Although some of immunotherapy agents like depatuxizumab [3] manifested curing effects in recurrent glioblastoma patients, other agents including bevacizumab [4, 5] and PD-1/PD-L1 antibodies such as nivolumab [6, 7] and the like, which have been proven effective for the treatment of other tumors, are of limited value for primary glioma patients. The gene discussed is CD274; the disease is glioma.